[
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals - Dupixent sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid",
    "summary": "TARRYTOWN, PARIS - Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License...",
    "url": "https://finnhub.io/api/news?id=841c9b7882bdbe76075e3bc2c33515d1c4f637462a851c032b59c8b664e416a7",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1739965542,
      "headline": "Regeneron Pharmaceuticals - Dupixent sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid",
      "id": 132787527,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "TARRYTOWN, PARIS - Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License...",
      "url": "https://finnhub.io/api/news?id=841c9b7882bdbe76075e3bc2c33515d1c4f637462a851c032b59c8b664e416a7"
    }
  }
]